Allstate Stock Rises As Analysts Lift Price Targets

Allstate Corporation (The) stocks have been trading up by 4.82 percent amid optimism from strong earnings and improving underwriting results.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ALL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Keefe Bruyette & Woods raised its price target on Allstate from $260 to $266 and reiterated an Outperform rating, reinforcing confidence in the stock’s upside potential.
BMO Capital slightly raised its price target on Allstate to $250 from $249 and reiterated an Outperform rating, with the broader analyst consensus at an overweight rating and an average price target of about $243.
The company maintained its quarterly dividend at $1.08 per share, payable July 1 to shareholders of record on 2026/06/01, with the stock trading around $216.18 and up 0.81% on the day.
The board approved a regular quarterly common dividend of $1.08 per share payable 2026/07/01 and about $29.3M in quarterly preferred dividends, signaling continuity in its capital return policy.
Barclays cut its price target to $203 from $208 and kept an underweight rating, creating a clear divide between cautious and bullish Street views on Allstate.

Weekly Update Jun 01 – Jun 05, 2026: On Friday, June 05, 2026 Allstate Corporation (The) stock [NYSE: ALL] is trending up by 4.82%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Finance industry expert:

Analyst sentiment – positive

Allstate sits in the top tier of U.S. P&C insurers, with 2025 revenue of ~$67.7B growing high single digits and strong profitability (pretax margin 12.4%, total profit margin 17.5%). Capital efficiency is exceptional: ROE 48% LTM on 1.9x P/B and 4.8x P/E, implying the market is discounting earnings durability rather than growth. Free cash flow is robust at $3.5B+ this quarter versus $2.46B net income, easily funding a 2.0% dividend yield and buybacks with no net financial debt.

Technically, ALL is in a clear short-term uptrend, with closes stepping from ~$207 to $221 over the latest five sessions and no evidence of heavy supply on intraday (5‑minute) candles; pullbacks are shallow and quickly bought. The 210–211 zone, tagged multiple times and now left behind, is a high‑conviction near-term support and tactical stop level. Above, 220–222 is the immediate resistance area; sustained closes over 222 would likely trigger momentum buying toward the mid‑230s.

More Breaking News

Fundamentally and versus Finance/Insurance peers, ALL trades at a steep discount on P/E and price‑to‑free‑cash‑flow despite sector‑leading ROE, improving underwriting, and a secure dividend that is being reaffirmed. Recent analyst actions skew positive (KBW $266, BMO $250), with one notable underweight outlier at $203 that is increasingly disconnected from price action. With benign news flow, constructive capital returns, and strong cash generation, fair value sits at $250–260, with support at $210 and resistance at $230 then $250.

Quick Financial Overview

Allstate Corporation (The) is trading with constructive price action into the low $220s, supported by firm analyst sentiment and solid fundamentals. Weekly data show ALL climbing from the low $210s toward $221, with each recent bar closing near its high, a classic sign of sustained buying pressure rather than a quick short-covering spike. On the intraday tape, the 5‑minute chart shows a controlled grind higher from about $213 at the open to $221 into the close, with shallow pullbacks that keep making higher lows.

Under the hood, Allstate posts about $67.685B in revenue and a profit margin on total operations of 17.52%, which is strong for a large insurer. A price-to-earnings ratio around 4.81 and price-to-sales near 0.81 signal that traders are paying a low multiple for those earnings and revenues, at least on current numbers. Return on equity above 48% on a last‑twelve‑months basis and around 16.2% on a longer view shows that capital is being used efficiently.

Cash generation is another key pillar. Operating cash flow is roughly $3.562B for the latest quarter, with free cash flow of about $3.522B even after heavy investment activity, backing the $1.08 quarterly dividend and a dividend yield near 2%. A leverage ratio of 4.2 and premiums receivable of roughly $11.648B are normal for a scaled insurer, and recent dividends plus preferred payouts around $29.3M confirm management’s comfort with the balance sheet. For traders, this financial backdrop supports the bullish analyst targets in the $243–$266 range versus a spot price a bit above $220.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!